ONCT — Oncternal Therapeutics Balance Sheet
0.000.00%
- $1.56m
- -$13.02m
- $0.79m
Annual balance sheet for Oncternal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 20.1 | 117 | 90.8 | 63.7 | 34.3 |
Net Total Receivables | — | — | — | 0.178 | 0.632 |
Prepaid Expenses | |||||
Total Current Assets | 20.8 | 118 | 92.9 | 67.3 | 36.1 |
Net Property, Plant And Equipment | 0.19 | 0.04 | 0.075 | 0.087 | 0.258 |
Other Long Term Assets | |||||
Total Assets | 21.7 | 119 | 93.6 | 68.7 | 36.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.34 | 5.86 | 5.46 | 7.68 | 5.2 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.43 | 5.86 | 5.46 | 7.68 | 6.68 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 14.3 | 113 | 88.1 | 61 | 30.1 |
Total Liabilities & Shareholders' Equity | 21.7 | 119 | 93.6 | 68.7 | 36.7 |
Total Common Shares Outstanding |